Epic Bio Presents Compelling Preclinical Data Supporting Clinical Initiation of EPI-321 for FSHD
- NHP studies demonstrate EPI-321’s favorable safety and pharmacokinetic profile - - IND and CTA applications planned for 2023 - SOUTH SAN FRANCISCO, Calif., June 16, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company…